Yaz Kit
Product Images NDC 50419-405

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Yaz (NDC 50419-405). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bayer Healthcare Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formulas (0ed216ab 0c5e 4e77 8170 114a2c530ae7 03)

Chemical structure diagrams of the active ingredients Drospirenone and Ethinyl Estradiol shown side by side.*

FDA Label Image

Blister (0ed216ab 0c5e 4e77 8170 114a2c530ae7 04)

Yaz (drospirenone and ethinyl estradiol) kit dosage form panel showing a day-label placement area with a series of circular cutouts arranged in four rows. The label includes the active ingredients and strength, 3 mg/0.02 mg, printed beneath the circles. Arrows indicate the order of day placement across the rows.*

FDA Label Image

Likelihood Of Developing A Serious Blood Clot (0ed216ab 0c5e 4e77 8170 114a2c530ae7 05)

A horizontal bar graph illustrating the number of women with a blood clot per 10,000 women years for four groups: Non-Pregnant Non-COC users, COC users, Pregnancy, and Postpartum (12 weeks only). The bars show ranges with Postpartum having the highest range from 40 to 65, and Non-Pregnant Non-COC users the lowest range from 1 to 5.*

FDA Label Image

Carton (0ed216ab 0c5e 4e77 8170 114a2c530ae7 06)

Yaz (drospirenone and ethinyl estradiol) kit packaging label by Bayer HealthCare Pharmaceuticals Inc. It contains 28 oral tablets with a strength of 3 mg drospirenone and 0.02 mg ethinyl estradiol per tablet. The front panel displays the product name prominently along with dosage form and quantity details.*

FDA Label Image

50419 0405 01 Splimage30 Be195f3a

Round pink tablet with an imprint of a hexagon enclosing the letters 'DS' on one side, plain on the other side. This pill corresponds to Yaz, a kit form prescription drug containing drospirenone and ethinyl estradiol, manufactured by Bayer HealthCare Pharmaceuticals Inc.*

FDA Label Image

50419 0405 01 Splimage30 C11960eb

Close-up image of a white, round tablet imprinted with 'DP' inside a hexagon on one side and plain on the other. This tablet is a dosage form associated with the prescription drug Yaz, containing drospirenone and ethinyl estradiol.*

FDA Label Image

Fig 1 (Image 01)

A forest plot comparing hazard ratios, rate ratios, and odds ratios from various studies including Ingenix, EURAS, LASS, FDA-funded, Danish, MEGA, German case-control, PharMetrics, and GPRD. The studies are grouped by prospective cohort, retrospective cohort, case-control, and non-fatal idiopathic case categories. The horizontal axis presents a log scale ranging from 0.1 to 10 for these ratios.*

FDA Label Image

Chart (Image 02)

A vertical scale chart illustrating the relative effectiveness of various birth control methods. It categorizes methods by pregnancies per 100 women per year, with 'Fewer Pregnancies' at the top and 'More Pregnancies' at the bottom. Methods range from implants, injections, intrauterine devices, and sterilization at the top, followed by birth control pills, skin patches, vaginal rings, then condoms and diaphragms, with behavioral methods like abstinence, spermicide, and withdrawal lower, and no birth control at the bottom.*

FDA Label Image

Image 03

A bar chart illustrating the number of women with a blood clot out of 10,000 women years (WY) across four groups: non-pregnant non-COC users, COC users, pregnant women, and postpartum women (12 weeks only). The chart shows increasing ranges, with postpartum women having the highest range (40 to 65) and non-pregnant non-COC users the lowest (1 to 5).*

FDA Label Image

Image 04

A forest plot chart comparing effect estimates from various studies on contraceptive use categories, including Ever COC vs. Never COC Use and Current COC use vs. Never-Use. The chart displays odds ratios (OR), risk ratios (RR), and hazard ratios (HR) with confidence intervals for multiple studies from 2002 to 2017, plotted along an Effect Estimate axis ranging from approximately -1.50 to 2.00.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.